Table 3.
Univariate analysis of factors associated with response to Gemcitabine, Carboplatin, Dexamethasone, and Rituximab
| Factor | Response rate (%) | Odds Ratio for response (95% CI) | p - value |
|---|---|---|---|
| Chemoresistant* | |||
| Yes | 54 | 0.25 (0.06–1.05) | .06 |
| No | 82 | ||
| > 2 prior regimens | |||
| Yes | 73 | 1.63 (0.49–5.42) | .43 |
| No | 62 | ||
| Prior anthracycline | |||
| Yes | 67 | 1.24 (.26–9.96) | .79 |
| No | 63 | ||
| Prior platinum | |||
| Yes | 71 | 1.29 (0.22–7.47) | .77 |
| No | 66 | ||
| Prior rituximab** | |||
| Yes | 62 | 0 (---) | .13 |
| No | 100 | ||
| Prior transplant | |||
| Yes | 83 | 2.76 (.30–25.71) | .37 |
| No | 64 | ||
*
based on 45 patients with prior response data.
**
based on 34 with CD20+ lymphoma only